8
Nov
2017
The Long Run Podcast: Elias Zerhouni on the Role of Immigrants In Science
Today’s guest on The Long Run podcast is Elias Zerhouni. He’s the president of global R&D at Sanofi, one of the world’s biggest makers of drugs and vaccines. Zerhouni, for those unfamiliar, started out as an academic researcher in radiology at Johns Hopkins. He then became an entrepreneur, and worked his way up at Hopkins as an academic administrator. He...Read More 
Share:
6
Nov
2017
The Dark Underbelly of Startup Fundraising: Working Through Self-Doubt, Loneliness
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
3
Nov
2017
Amazon Prowling the Drug Supply Chain, Celgene’s Ho-Hum Bounceback & a Couple More IPOs
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
2
Nov
2017
Understanding Polio, Baseball and Cancer: Sometimes the “When” is as Vital as the “What”
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
30
Oct
2017
Atlas, Amgen, Lilly Bet $30M for Kymera’s Imaginative Protein Degradation
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Oct
2017
Activist FDA Boss Zeroes in on Opioid Crisis, PTC Shot Down, and CRISPR 2.0 Buzz
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
26
Oct
2017
VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch
Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson...Read More
Share:
25
Oct
2017
Richard Pops on Fighting the Opioid Painkiller Crisis
Today’s guest on “The Long Run” podcast is Richard Pops. He’s the chairman and CEO of Alkermes. He is one of the seniormost executives in the biopharma industry, having joined Alkermes as CEO back in 1991. The company is known for its technology around making long-lasting injectable drugs, especially for mass-market chronic diseases like schizophrenia and diabetes. I’ve known Pops...Read More
Share:
24
Oct
2017
AbbVie Shells Out $205M Upfront for Alector’s Antibodies Vs. Alzheimer’s
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
23
Oct
2017
BioMarin Book Contains Rare Insight Into the Rare Disease Business
Companies, usually around an anniversary, often pat themselves on the back with airbrushed or whitewashed coffee table books. They chronicle all the wonderful things they’ve done. Maybe there was an amusing screw-up or two along the way. Toss in a few funny photos of the founders in Coke-bottle glasses and fat ties, and call it good. As for the nitty-gritty...Read More
Share:
20
Oct
2017
Gilead’s Thrilling CAR-T Victory, Celgene’s Agonizing Crohn’s Defeat, & Vir Goes Big
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
18
Oct
2017
Vir Biotechnology, a ‘Shock and Awe’ Startup, Bets on Infectious Disease with $500M+
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
17
Oct
2017
VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
16
Oct
2017
Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
13
Oct
2017
Spark Gene Therapy Sails Thru AdComm, Broad Institute Nuzzles Up to Deerfield, Pfizer’s Cancer Deal in Africa
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
11
Oct
2017
George Yancopoulos on Threading the Price Needle, and Building a Biotech to Last
George Yancopoulos, the president and chief scientific officer, started his biotech career in 1989 at Regeneron Pharmaceuticals. He’s been there ever since, and has pretty much seen it all. It was a pleasure to have him as the guest for Episode 3 of The Long Run podcast. Yancopoulos, in this recording at Regeneron offices in Tarrytown, NY, talks about how...Read More
Share:
9
Oct
2017
Where Does Alzheimer’s R&D Go Now? Plenty of Directions
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
6
Oct
2017
IPO Market Finds a Rhythm, FDA Huddles with FTC on Pricing, & Praluent Gets to Stay
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
3
Oct
2017
Nimbus Rinses and Repeats, Enticing Celgene With Immunology Drug Candidates
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
2
Oct
2017
KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
